Published • loading... • Updated
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains
Summary by MarketBeat
1 Articles
1 Articles
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains
Iovance Biotherapeutics (NASDAQ:IOVA) said it is expanding its tumor-infiltrating lymphocyte, or TIL, therapy platform across multiple solid-tumor indications after reporting a record second quarter marked by nearly $100 million in revenue and a 56% margin. Speaking at the H.C. Wainwright 28th Annu
·Sioux Falls, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
